NEW YORK, August 27, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Express Scripts Holding Company (NASDAQ: ESRX) and C.R. Bard, Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5998-100free.
--
Gilead Sciences, Inc. Research Reports
Gilead Sciences, Inc. posted on the Events section of its official website that the Company will participate in the upcoming European Society of Cardiology Congress 2014, which is scheduled from August 30, 2014 through September 3, 2014 in Barcelona, Spain. The full research reports on Gilead are available to download free of charge at:
http://www.analystsreview.com/Aug-27-2014/GILD/report.pdf
--
AbbVie Inc. Research Reports
On August 18, 2014, AbbVie Inc. (AbbVie) announced that the Company will award $2,500 each to 40 outstanding students suffering from cystic fibrosis (CF) to pursue their undergraduate or graduate school education during the 2014-2015 school year through the AbbVie CF Scholarship program. AbbVie informed that public can vote for two of the 40 winners to earn the title of 2014 Thriving Undergraduate or Graduate Scholar on the Company's website until September 15, 2014. Jim Hynd, Vice President, GI Care, AbbVie, said, "The achievement and dedication shown by the AbbVie CF Scholarship recipients continue to impress us each year. Students with CF face significantly more mental, physical and emotional challenges than those who do not suffer the symptoms of this disease, and AbbVie is honored to support their academic endeavors as they become role models for the CF community." The full research reports on AbbVie are available to download free of charge at:
http://www.analystsreview.com/Aug-27-2014/ABBV/report.pdf
--
Pfizer Inc. Research Reports
On August 21, 2014, Pfizer Inc. (Pfizer) and Bristol-Myers Squibb Company (Bristol-Myers) jointly announced that the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application (sNDA) for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. The Company informed that FDA's approval is based on data from the global AMPLIFY and AMPLIFY-EXT studies. Steve Romano, Senior Vice President, Head of Medicines Development Group for Global Innovative Pharmaceuticals, Pfizer, said, "DVT, which may lead to PE, can be a serious medical condition, with PE requiring immediate medical attention for treatment. Once a VTE has occurred, approximately 33 percent of patients are at risk of a recurrence within 10 years." The full research reports on Pfizer are available to download free of charge at:
http://www.analystsreview.com/Aug-27-2014/PFE/report.pdf
--
Express Scripts Holding Company Research Reports
On August 22, 2014, shares in Express Scripts Holding Company (Express Scripts) declined 0.42% to end the trading session at $75.03, underperforming the Nasdaq Composite that gained 0.14% over the same trading session. Express Scripts' stock initiated the session at $75.10 and oscillated in the range of $75.01 - $75.47. The stock has a 52-week high of $79.37 and a 52-week low of $59.20. Over the past three months, the stock has returned 6.97% underperforming the Nasdaq Composite that returned 8.43% over the same period of time. The full research reports on Express Scripts are available to download free of charge at:
http://www.analystsreview.com/Aug-27-2014/ESRX/report.pdf
--
C.R. Bard, Inc. Research Reports
On August 22, 2014, C.R. Bard, Inc. (Bard) stock declined 1.14% to end the trading session at $147.00, extending its losses from previous three trading sessions. Bard's stock opened the session at $149.04 and fluctuated between intra-day low of $146.97 and intra-day high of $149.04. Over the past three months and six months, the stock has strengthened 0.26% and 3.84% respectively. The shares of the Company are trading below their 50-day and 200-day moving average of $147.2 and $147.76, respectively. The full research reports on Bard are available to download free of charge at:
http://www.analystsreview.com/Aug-27-2014/BCR/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
